Affinity Asset Advisors »

Avalo Therapeutics Ord shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Avalo Therapeutics Ord (AVTX) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Avalo Therapeutics Ord

Tip: Access up to 7 years of quarterly data

All positions including Avalo Therapeutics Ord held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Avalo Therapeutics Ord by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $561k 45k 12.47
2024-03-31 $218k 10k 21.75

More positions owned by Affinity Asset Advisors

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Madrigal Pharmaceuticals (MDGL)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Celldex Therapeutics Com New (CLDX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Alnylam Pharmaceuticals Note 1.000% 9/1 (Principal)
Beigene Sponsored Adr (BGNE)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)

View all positions for Affinity Asset Advisors

Top funds holding Avalo Therapeutics Ord

Logos Global Management
Sio Capital Management
Ikarian Capital
Affinity Asset Advisors
Commodore Capital
Vanguard Group
Bank of America Corporation
Royal Bank of Canada
Banque Cantonale Vaudoise
BlackRock
Morgan Stanley
Efficient Wealth Management
Bnp Paribas Arbitrage, Snc
Group One Trading
Jpmorgan Chase & Co

View all funds holding Avalo Therapeutics Ord